Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tien Liang BioTech Co (ROCO:4127) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Tien Liang BioTech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$3,527.3 Mil.
Tien Liang BioTech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$82.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tien Liang BioTech Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tien Liang BioTech Co's EV-to-EBIT falls into.
Tien Liang BioTech Co's current Enterprise Value is NT$3,211.3 Mil.
Tien Liang BioTech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$82.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tien Liang BioTech Co (ROCO:4127) has a EV-to-EBIT of 39.05 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tien Liang BioTech Co and its competitors. According to the industry distribution chart, Tien Liang BioTech Co ranks #537 out of 682 companies in the Drug Manufacturers industry, placing it in the top 78.7%.
Is Tien Liang BioTech Co's EV-to-EBIT too high?
Tien Liang BioTech Co's current EV-to-EBIT is 39.05. The Drug Manufacturers industry median EV-to-EBIT is 16.03. Tien Liang BioTech Co's value of 39.05 is 143.7% above this industry median. Based on the distribution chart, Tien Liang BioTech Co ranks #537 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tien Liang BioTech Co has a GF Score™ of 49/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tien Liang BioTech Co ranks #537 out of 682 companies for EV-to-EBIT. This places Tien Liang BioTech Co in the lower half of its industry. The industry median EV-to-EBIT is 16.03. Tien Liang BioTech Co's value of 39.05 is 143.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.03, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tien Liang BioTech Co's current EV-to-EBIT of 39.05 is 143.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tien Liang BioTech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tien Liang BioTech Co's current EV-to-EBIT is 39.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$52.76, compared to a current price of NT$61.40 — trading 16.4% above its estimated fair value. The current EV-to-EBIT is 39.05 and 143.7% above the Drug Manufacturers industry median of 16.03. Tien Liang BioTech Co's overall GF Score™ is 49/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current EV-to-EBIT is 39.05 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?
Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued.
The current stock price of NT$61.40 is trading 16.4% above its estimated GF Value™ of NT$52.76.
GuruFocus considers Tien Liang BioTech Co to be Modestly Overvalued.
Key valuation signals for ROCO:4127:
EV-to-EBIT: 39.05
GF Value™: NT$52.76 vs. price of NT$61.40 (16.4% above fair value)
Industry Position: 143.7% above the Drug Manufacturers median (#537 of 682)
No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
49GF Score
Get the complete analysis for ROCO:4127
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4127 has been successfully added to your 
